anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Thyroglobulin is a well-established disease marker during follow-up in paediatric differentiated thyroid cancer. However, no conclusive data on the role of endogenously stimulated thyroglobulin after thyroidectomy (ptTg) in predicting disease-specific outcomes are available. This review aims to establish the prognostic value of ptTg in children with DTC.
METHODS: Online medical databases were searched for studies evaluating the association between ptTg and disease-specific outcomes in DTC-affected children. Documents not in English, preclinical studies, other review articles, case reports, and small case series were excluded. The risk of bias was assessed with the QUADAS-2 tool.
RESULTS: Twelve studies, analysing 1043 children in total, were included in the review. They all had a retrospective design and were published between 2016 and 2022. Of all patients, 1008 (97%) and 849 (81%) had undergone thyroidectomy and RAI, respectively. Eight studies (756 children) evaluated the correlation between ptTg and disease persistence/relapse: six reported a significant association between these parameters; a specific ptTg cut-off (10-14 ng/ml) was identified at the multivariate analysis in three studies. The remaining four studies assessed the link between ptTg levels and disease extension, with three reporting a correlation between ptTg and lung/nodal metastases.
DISCUSSION: ptTg is a readily available and inexpensive parameter, bearing a strong prognostic power in identifying disease persistence, relapse, and the presence of metastases in children affected by DTC.
Children and youth living with cerebral palsy will take part in a 60-hour intensive bimanual therapy at Peps at Université Laval, during which they will play games and exercise to promote spontaneous use of the most affected hand. Participants will take part to pre-evaluation and 1-week and 6-month post-intervention.
PURPOSE:To efficiently separate lymphocyte subclass by bringing a liquid to be tested into contact with a separating agent for lyphocyte subclass prepared by coupling oxirane-acrylic beads with an oxyalkylamine so that the B- lymphocyte and nonlymphocyte luekocyte are selectively adsorbed to the separating agent. CONSTITUTION:The separating agent for lymphocyte subclass is prepared by coupling an oxyalkylamine with glycidyl group of oxirane-acrylic beads as an insoluble carrier. The liquid to be tested is brought into contact with this separating agent so that the B-lymphocyte and nonlymphocyte luekocyte are selectively adsorbed to the separating agent. The oxirane-acrylic beads are polymers obtd. from the mixture of unsatd. radical-polymerizable monomers having oxirane groups and cross-linking monomers. Thereby, lymphocyte subclass cells which act an important roll for immunocyte in tissue or humor such as blood, especially, T-lymphocyte can be separated and corrected without damaging the function of the cell.
A method of delivering a discount on a purchasable item includes capturing a message of the item by a device. The device processes the message and sends a message artifact. A discount service computer receives and parses the message. The message is matched to a record of an eligibility database, if any exist in the eligibility database, or else a corresponding record for the message is generated. A discount database is accessed for a discount coupon relevant to the record and the purchasable item identity. The discount coupon is sent to the device. The item is discounted at point of purchase, and the applicable record of the discount database is updated.
BACKGROUND: The prevalence of obesity has increased significantly in recent decades. Today, it is estimated that more than one-third of the world's population has overweight or obesity, rendering it one of the most significant global health concerns. This article provides a current estimate of the direct costs associated with managing overweight and obesity, including treatment of related complications, among adolescents (≥15 years) and adults in Switzerland.
METHODS: Prevalence of overweight and obesity based on the BMI reported in the 2017 Swiss Health Survey was extrapolated to 2021. Systematic literature searches were performed to identify treatment costs and epidemiological data of obesity-related complications and costs were extrapolated to 2021. Costing methodology was based on available source data for individual related complications. Treatment costs for complications attributable to overweight and obesity were estimated by applying their population attributable fraction (PAF).
RESULTS: More than 3.1 million inhabitants of Switzerland aged ≥15 years met the criteria for overweight or obesity in 2021. The prevalence of overweight increase over the past decades from 30.4% in 1992 to 41.9% in 2017 while prevalence of obesity doubled from 5.4 to 11.3%. Overall, the total attributable costs of overweight and obesity caused by seven assessed obesity-related complications (asthma, coronary heart disease, depression, diabetes mellitus, hypertension, osteoarthritis, and stroke) are estimated at CHF 3657-5208 million with most of the costs (97-98%) caused by the assessed obesity-related complications. Only 2-3% of the total costs were attributable to the combined direct management of overweight and obesity by bariatric surgery (CHF 83 million), pharmacological therapy (CHF 26 million) and dietary counseling (CHF 18 million).
CONCLUSION: Overweight and obesity impose a significant cost impact on the Swiss healthcare system, accounting for 4.2-6.1% of total healthcare expenditures in 2021. Notably, direct treatment of overweight and obesity accounts for only 0.08-0.18% of the total healthcare expenditures. The analysis also revealed a significant lack of available health economic evidence, necessitating the use of assumptions and approximations in this estimation. This is noteworthy, as respective data would be available in healthcare systems but are either unpublished or inaccessible.
A method and system for determining anaerobic threshold intensity (AnT) of a user in a freely performed physical exercise. A physiological response of a user is measured by heart rate and measured heart rate values are recorded as heart rate data. An external workload values are recorded and are each associated with one measured heart rate values to form a plurality of data points. The data points are filtered to form accepted data points, which are classified within a plurality of heart rate segments representing a heart rate within an anaerobic threshold (AnT) of the user. A data point with highest probability is stored for each segment. A first probability factor for each accepted data point is calculated. The calculated first probability factor is compared to a stored probability factor in each segment, and the higher probability factor is retained. AnT is calculated using the stored probabilities in each segment.
PURPOSE: A myostatin inhibitor including a DLK1 extracellular water-soluble domain as an active ingredient is provided to prevent and treat a disease that needs muscular cell differentiation including muscle microsomia or metabolic diseases by hindering mechanism of myostatin as the inhibitor binds to the myostatin or activin receptor type 2B. CONSTITUTION: A composition for myostatin activity inhibition comprises adelta-like 1 homolog (DLK1) extracellular water-soluble domain, a fraction of a DLK1 extracellular water-soluble domain, or a mutant or a fraction of the mutant of a DLK1 extracellular water-soluble domain as an active ingredient. The DLK1 extracellular water-soluble domain has an amino acid sequence represented by SEQ ID No. 29. The composition for myostatin activity inhibition comprises a DLK1 extracellular water-soluble domain or a fraction thereof, and a DLK1-Fc fused protein to which a human antibody Fc region is fused as an active ingredient. A pharmaceutical composition for preventing or treating a myostatin-related disease comprises a DLK1 extracellular water-soluble domain, a fraction of a DLK1 extracellular water-soluble domain, or a mutant of a DLK1 extracellular water-soluble domain or a fraction of the mutant as an active ingredient.
Disclosed is a low-odor thickening/foam boosting agent having foam boosting/thickening properties. Also disclosed is a cleaning composition containing such a thickening/foam boosting agent. Specifically disclosed is a thickening/foam boosting agent composed of the following component (A). (A) A compound represented by the following general formula (1). R1O-(PO)n/(EO)m-R2 (1) (In the formula, R1 represents a linear alkyl group having 8-10 carbon atoms or an alkenyl group; PO represents a propyleneoxy group; EO represents an ethyleneoxy group; the average added mole number n is a number of 1.5-3.0; the average added mole number m is a number of 0-1.0; and R2 represents a hydrogen atom or a methyl group.) The alcohol content, which is represented by the above formula (1) with n being 0, m being 0 and R2 being a hydrogen atom, is not more than 3000 ppm. Also specifically disclosed is a cleaning composition containing the above component (A) and a surface active agent (B).
PROBLEM TO BE SOLVED: To provide the subject new cell produced by fusing a malignant B cell originating from a patient to a hybridoma cell capable of producing an antibody bonding to a surface antigen on an antigen presenting cell, inducing tumor immunity and useful e.g. as an agent for the treatment of B cell malignant diseases. SOLUTION: This new hybridoma is producible by fusing a malignant B cell originated from a patient to a hybridoma cell capable of producing an antigen bonding to a surface antigen on an antigen presenting cell. Tumor immunity can be induced by injecting the hybridoma into a patient of B cell neoplasia and the hybridoma is useful e.g. as a new agent for the treatment of human B cell malignant disease. The new hybridoma is produced by fusing a malignant B cell such as B cell leukemia cell, B cell lymphoma cell or plasmacytoma cell to a hybridoma cell obtained by fusing a lymphocyte producing an antibody against a surface antigen on an antigen presenting cell to a lymphoma cell by conventional fusion process.
A process for the isolation and purification of immunologically active polyribosyl ribitol phosphate (PRP), the capsular polysaccharide of Haemophilus influenzae type b. The PRP has been purified with ethanol, Cetavlon (hexadecyltrimethyl ammonium bromide) and a phosphate containing adsorbent, hydroxylapatite. The contaminants (nucleic acid, proteins and endotoxins) are removed to the minimum level by a treatment with hydroxylapatite. Also described is a process for the preparation of a combined vaccine containing the PRP (prepared as aforementioned) and B. pertussis antigens. The vaccine elicits anti-PRP antibody and antipertussis antibody (as measured by microagglutination) formations in young animals. This sera with anti-PRP antibody exhibits a strong bactericidal activity.
NEW MATERIAL:A compound expressed by formula I [A and B represent (halogen-substituted) lower alkanoyloxy or link together to represent formula II and III (R<1> and R<2> represent H, OH or lower, alkyl, or link together with the adjacent C, to form a cyclobutane ring), etc.]. EXAMPLE:Oxalato (1,3-diamino-2-propanol) platinum (II). USE:An antitumor agent with low toxicity. PREPARATION:For example, potassium iodide is added to an aqueous solution of potassium chloroplatinite K2[PtCl4]. Into thus formed aqueous solution of platinous potassium iodide, is added 1,3-diamino-2-propanol to carry out the reaction and afford a compound expressed by formula IV. Then this compound is treated with silver nitrate in an aqueous solution to form a dinitrato complex expressed by formula V, which is further reacted with a desired carboxylate.
The aim of this study is to design, implement and evaluate a telephone-based intervention using cognitive-behavioral approach for first-time mothers during the immediate postpartum period. The objective is to evaluate the effect of a telephone-based intervention using cognitive-behavioral approach on postnatal depression and quality of life at 6 weeks and 6 months postpartum.

A longitudinal, randomized, pre and post-test control group design will be used. This design involves providing a 5-week telephone-based intervention using cognitive-behavioral approach at the immediate postpartum period (first five weeks postpartum) to women with high risk of postnatal depression. The experimental group receives the intervention on top of the usual postpartum care, while the control group receives the usual postpartum care only. Participants will be recruited through the postnatal wards at three regional public hospitals in Hong Kong. Eligible participants will be randomly assigned to either the telephone-based intervention or control group. The allocation schedule will be prepared in advanced using a restricted randomization scheme (random permutated blocks of six) by a random number table. The random numbers will be placed in sequentially numbered, opaque and sealed envelopes. After the women have given informed written consent at 2-3 days postpartum at the postnatal units, the research assistant will open the envelope containing the group assignment.

Participants will be postpartum women who meet the inclusion and exclusion criteria. The research nurse will determine if the women meet the sample inclusion criteria from their records. Potential eligible participants will be approached on the second or third postpartum day at the postnatal units. Women will be provided with essential information on the nature of the study and invited to complete the EPDS. Women who score above 9 on EPDS are considered at risk of postnatal depression and they will be invited to participate in the study. Verbal and written explanations of the purpose and the procedure of the study will be provided by the research nurse and written consent will be obtained from women who agree to participate in the study. Participants will be asked to complete the baseline measures, including EPDS and SF-12. Post-test measures will be collected at 6 weeks and 6 months postpartum through mail.
While neurosurgical interventions are frequently used in laboratory mice, refinement efforts to optimize analgesic management based on multimodal approaches appear to be rather limited. Therefore, we compared the efficacy and tolerability of combinations of the non-steroidal anti-inflammatory drug carprofen, a sustained-release formulation of the opioid buprenorphine, and the local anesthetic bupivacaine with carprofen monotherapy. Female and male C57BL/6J mice were subjected to isoflurane anesthesia and an intracranial electrode implant procedure. Given the multidimensional nature of postsurgical pain and distress, various physiological, behavioral, and biochemical parameters were applied for their assessment. The analysis revealed alterations in Neuro scores, home cage locomotion, body weight, nest building, mouse grimace scales, and fecal corticosterone metabolites. A composite measure scheme allowed the allocation of individual mice to severity classes. The comparison between groups failed to indicate the superiority of multimodal regimens over high-dose NSAID monotherapy. In conclusion, our findings confirmed the informative value of various parameters for assessment of pain and distress following neurosurgical procedures in mice. While all drug regimens were well tolerated in control mice, our data suggest that the total drug load should be carefully considered for perioperative management. Future studies would be of interest to assess potential synergies of drug combinations with lower doses of carprofen.
FIELD: biotechnology. SUBSTANCE: human abortive serum is mixed with product obtained by mixing serum with antibodies raised to human alpha- fetoprotein with normal human serum in the ratio 10:1. Mixture is centrifuged, precipitate is dissolved in physiological solution, pH = 2, cooled ethyl alcohol is added to solution in the ratio 1:1 followed by centrifugation. Cooled ethyl alcohol is added again to the remained solution in the ratio 2: 1. After centrifugation precipitate is obtained that is a human alpha-fetoprotein with purity 90%, not less. Polysaccharide is added to the obtained alpha-fetoprotein followed by package and lyophilic drying. EFFECT: decreased cost, high purity of end product, simplified method. 2 cl
An absorbable bone substitute, bone cpd. or prothesis anchoring compsn. comprises a mixt. of calcined K phosphates (I) with a biodegradable polymer (II). (I) contains CaO and P2O5 in a ratio of 2-4:1. The compsn. is implanted as a solid body. Compsn. may be worked on and adjusted during the operation and forms a high load carrying bond between the tissue and prothesis. Both (I) and (II) are absorbable and replaced gradually by natural tissue. The material accelerates growth of the bone on the surface of the ceramic.
Atrial fibrillation (AF) is currently defined as symptomatic by asking patients if they are aware of when they are in AF and if they feel better in sinus rhythm. However, this approach of defining AF as symptomatic and asymptomatic fails to adequately consider the adverse effects of AF in patients who are unaware of their rhythm including progression from paroxysmal to persistent AF, and the development of dementia, stroke, sinus node dysfunction, valvular regurgitation, ventricular dysfunction, and heart failure. Labeling these patients as asymptomatic falsely suggests that their AF requires less intense therapy and puts into question the notion of truly asymptomatic AF. Because focusing on patient awareness ignores other important consequences of AF, clinical endpoints that are independent of symptoms are being developed. The concept of AF burden has more recently been used as a clinical endpoint in clinical trials as a more clinically relevant endpoint compared to AF-related symptoms or time to first recurrence, but its correlation with symptoms and other clinical outcomes remains unclear. This review will explore the impact of AF on apparently asymptomatic patients, the use of AF burden as an endpoint for AF management, and potential refinements to the AF burden metric. The review is based on a presentation by the senior author during the 2023 16th annual European Cardiac Arrhythmia Society (ECAS) congress in Paris, France.
Each study bottle will contain 60 capsules of placebo, which is lactose monohydrate and will be supplied in clear plastic capsules identical to the budesonide capsules. Subjects will be required to dissolve the contents of two capsules into the 8-ounce (240 ml) NeilMed Sinus Rinse Regular Bottle along with the saline rinse. All subjects will be instructed to irrigate both right and left nasal cavity with one-half of the contents of the nasal rinse once daily.
Gemcitabine + rapamycin at recommended dose of Phase 1. Recommended dose is defined as, the dose one level below of the (MTD). Being MTD, the dose of the cohort in which a maximum of one patient of 6 has presented dose-limiting toxicity (DLT).
BACKGROUND: The microscopic middle ear surgery involves a limited operating space and numerous important anatomical structures in which good visualization is crucial, as even a small amount of bleeding can greatly affect the clarity of surgical field. This study aims to investigate whether intravenous 1 g of tranexamic acid can improve surgical visualization and further shorten the operation time in microscopic middle ear surgery.
METHODS: This study is a prospective, randomized, double-blind, controlled trial conducted from December 2021 to December 2022, enrolling patients who were scheduled for microscopic modified radical mastoidectomy due to chronic otitis media. In addition to standard techniques to optimize the surgical field, participants were randomized into the TXA (tranexamic acid) group (1 g diluted to 20 ml normal saline) and the control group (20 ml normal saline). The primary outcome was assessed based on the clarity of the surgical field using the Modena Bleeding Score. Secondary outcomes included operation time, the surgeon satisfaction with the visual clarity, postoperative 24 h coagulation parameters, and the incidence of adverse events. Student's t -test, χ2 test, and ANOVA of repeated measures were used for statistical analyses.
RESULTS: A total of 28 patients were enrolled in each group using a 1:1 randomized allocation with similar demographic characteristics, including 24 male and 32 female individuals, and the mean age is 45.6±11.9 years. The surgical visualization in the TXA group was significantly better than that of the control group (2.29±0.46 vs. 2.89±0.31, P <0.001) as assessed by the Modena Bleeding Score. Furthermore, the TXA group demonstrated a shorter operation time compared to the control group (88.61±10.9 vs. 105.2±15.9, P <0.001) and higher surgeon satisfaction with surgical field (7.82±0.55 vs. 6.50±0.64, P <0.001). No statistically significant differences were found in postoperative coagulation parameters in the two groups. No TXA-related adverse events or complications occurred during the 12-month follow-up.
CONCLUSION: Intravenous 1 g of TXA can further significantly improve the visual clarity in the microscopic middle ear surgery and shorten the operation time based on other standard measures implemented.
16 well trained male long distance Triathletes participates in the study (30.65 ± 10.77 years of age), with minimum one year of triathlon competition experience and 8-10 hours of training per week. All subjects had a personal interview made by a registered Medical Doctor about the diet intervention prior to the beginning of the study. Moreover participants were educated about the benefits and limitations of the two different dietary treatments and asked to nominate their preference for, or non-acceptance of, each of these interventions. Thus participants also decided liberally if participate for the diet intervention or not. This choice was decided to prevent any type of dropout in the KD group, considering that a free and conscious choices is better for the adherence on a strict diet like ketogenic diet . Investigators were thus able to allocate the athletes to their preferred treatment, while achieving suitable matching of groups based on age, body mass and aerobic power. All the participants were healthy and injured free, and not consuming a low carbs diet prior to the study. The diet macronutrient percentage distribution was the following: for ND the percentages were 25% of TDC (total daily calories), fat were 20% of TDC and carbohydrates represented the 55% of TDC; for KD the percentages were 68% fat, 26% protein and 6% carbohydrate. In the KD very low carbohydrate foods that simulate carbohydrates taste food like croissants, bread and cracked slices made by Le Gamberi Foods (Forlì, Italy), were used for a better compliance to the dietary intervention. Subjects undertaken an anthropometric test and two different cardiopulmonary tests with a professional cycloergometer (MARCA). The anthropometric measures were taken to evaluated body weight. height and body composition . After the body composition analysis subjects underwent to a maximal cardiopulmonary test (GXT) to evaluate the maximal oxygen consumption (VO2max). The following day subjects performed 60 minutes at 45% of PPO to assess endurance performance at ironman biking race-pace. The day after test session KD group started the KD 5 weeks. The Control Group (S) followed his habitual normo-caloric, balanced diet. The same order and procedures were conducted for testing the subjects post diet intervention. Anthropometric and performance test was conducted in the same order for each subjects and at the same time of the day. Blood ketones were measured each other day to ensure the compliance to KD
We will send the study participate a daily text message for 2 months to their phone at 8 A.M. and a weekly text message for 6 months asking them to report their weight through a 2-question online survey. After that, a monthly text message for 18 months asking them to report their weight.